

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[← Back](#)

[Find a Clinical Trial](#)

[Refer a Patient](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

of tasks designed to help shift mental habits that may be linked to increased anxiety.

Participants in this study will be randomly assigned to use iThrive and a symptom tracking app, or a symptom tracking app alone for a 4-week period. Those assigned to iThrive will be asked to complete 8 or 16 sessions using the app. In addition, participants will complete questionnaires at the start of the study, after completing the intervention, and three months later to evaluate the apps.

[View the Privacy Policy for this app](#)

Who Can Join

This study will include people age 18 and older who have completed active treatment for a stage I-III rare cancer and/or breast cancer. Eligible rare cancer diagnoses include rare melanoma subtypes (acral, uveal, mucosal), Kaposi sarcoma, Merkle cell carcinoma, sebaceous cell carcinoma, rare gynecological cancers (vaginal, vulvar, ovarian, uterine, fallopian tube), and pediatric cancers. People with other rare cancer diagnoses may be eligible. All participants must have access to an iOS device (iPhone or iPad). [Learn if you are eligible to participate in this study](#).

Contact

For more information, please contact the research staff at AIMStudy@mskcc.org or [646-608-8446](tel:646-608-8446), or contact [Dr. Wendy Lichtenthal](#) at [646-608-8204](tel:646-608-8204).

Protocol

11-204

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence:
An Intervention Development Study

Phase

Pilot (small research study)

Investigator

[Christian J. Nelson](#)

Co-Investigators

[William S. Breitbart](#)

Diseases

[AIDS-Associated Cancers](#) › [AIDS-Associated Kaposi's Sarcoma](#)

[Breast Cancer](#)

[Gynecologic Cancer](#) › [Cervical Cancer](#)

[Gynecologic Cancer](#) › [Ovarian Cancer](#)

[Gynecologic Cancer](#) › [Uterine \(Endometrial\) Cancer](#)

[Gynecologic Cancer](#) › [Vulvar Cancer](#)

[Leukemia](#)

[Lymphoma](#)

[Melanoma](#)

[Neuroblastoma](#)

[Pediatric Brain Tumors](#)

[Pediatric Liver Tumors](#)

[Psychiatry & Behavioral Sciences](#)

[Spine Tumors](#)

[Survivorship](#)

Locations

[Memorial Sloan Kettering Cancer Center](#)

ClinicalTrials.gov ID

NCT01517945

ClinicalTrials.gov

[Visit ClinicalTrials.gov for full clinical trial description](#)

Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



▼ About MSK

[About us](#)

[Careers](#) ■

[Giving](#) ■

▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▼ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center